Last reviewed · How we verify
AR1001
AR1001 is a small molecule that targets the SGLT2 receptor.
AR1001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AR1001 |
|---|---|
| Sponsor | AriBio Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the SGLT2 receptor, AR1001 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) (PHASE3)
- Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AR1001 CI brief — competitive landscape report
- AR1001 updates RSS · CI watch RSS
- AriBio Co., Ltd. portfolio CI